US Patent Issued to Universitaet Basel on July 15 for "Virulence attenuated bacteria based protein delivery" (Swiss Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,358,955, issued on July 15, was assigned to Universitaet Basel (Basel, Switzerland).

"Virulence attenuated bacteria based protein delivery" was invented by Simon Ittig (Bottmingen, Switzerland), Marlise Amstutz (Basel, Switzerland) and Christoph Kasper (Olten, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject."

The patent was filed on Oct. 18, 2022, under Application No. 18/047,586.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/np...